Nav: Home

Texas Biomed receives NIH grant to study papillomavirus-based AIDS vaccine

April 30, 2015

SAN ANTONIO (April 30, 2015) - Scientists at Texas Biomedical Research Institute have begun work on a nearly $3.4 million study funded by the National Institutes of Health over the next four years to create an attenuated, or weakened, virus that is a hybrid of the papilloma virus and the human immunodeficiency virus, with the potential to jumpstart a body's immune response to develop antibodies against both viruses. This study is being done in Rhesus macaques using a form of the rhesus (Rh)PV and monkey HIV or Simian Immunodeficiency virus (SIV).

Dr. Marie-Claire Gauduin, an associate scientist in the Virology and Immunology Department, is leading this effort to develop and test a potential Human papillomavirus (HPV)-based HIV vaccine in monkeys that uses a new strategy integrating a recombinant rhesus papillomavirus (rRhPV) to induce virus-specific immune responses at mucosal genital sites to protect against both HIV and HPV transmission.

"This strategy would represent the first attempt to immunize animals with a trans-complementing live attenuated RhPV-SIV vector virus replicating at the major port of entry of SIV/HIV and RhPV/HPV, which is the mucosa," Gauduin said. "The study will also explore the feasibility of such vaccine delivery platforms to stimulate the mucosal (adaptive and/or innate) immune responses to restrict viral entry."

According to Dr. Gauduin, an ideal vaccine should provide life-long immunity against HIV infection at the site of transmission using viral antigens (or special regions or genes encoding for viral antigens that elicit an immune response) and should focus that immune response at the site of primary replication of HIV, which is the mucosa.

The first step in the study will be to create the hybrid virus that leads to long-term expression of SIV antigens. The second part of the study will investigate the nature of the immune response to the virus followed by investigation of the protective efficacy of the hybrid vaccine when challenged with actual SIV virus.

Nearly 80 percent of HIV infection is spread through mucosa. Gauduin's strategy will use the host's epithelial or skin stem cells as a mucosal delivery system to carry the hybrid virus throughout the mucosal site of infection and keep the immune response on alert.

"What's exciting about this is that if we can place the vector vaccine in just the right layer of the mucosa, it will promote antibody production and anti-SIV central memory CD8+ T cell expansion at the site of infection for a prolonged period of time, initiating the immune system, preventing HIV infection and/or propagation and generate immediate protection," Gauduin said.

She added, "In addition, we will generate anti-SIV cell expansion within the vaginal and rectal mucosa. Remember, skin grows out and sheds creating new layers of skin. As it does this, we hope to create an antibody response memory in the mucosal layer so that as skin regenerates, future layers retain this immune response. In other words, this novel HIV vaccine strategy will use the host epithelial stem cells as mucosal 'delivery systems' to 'carry' viral antigen and keep the immune response in alert at site of viral infection."

Currently there is no efficient vaccine developed to prevent transmission of the Human Immunodeficiency Virus (HIV), the agent responsible for Acquired Immunodeficiency Syndrome (AIDS).

According to Gauduin, "The development of an effective vaccine that restricts viral replication at mucosal portals of entry remains our best hope for controlling the HIV pandemic."
-end-
This study is currently being funded by an RO1 grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases for the study titled, "A trans-complementing Papillomavirus for AIDS Vaccine."

Texas Biomedical Research Institute

Related Hiv Articles:

Defective HIV proviruses reduce effective immune system response, interfere with HIV cure
A new study finds defective HIV proviruses, long thought to be harmless, produce viral proteins and distract the immune system from killing intact proviruses needed to reduce the HIV reservoir and cure HIV.
1 in 7 people living with HIV in the EU/EEA are not aware of their HIV status
Almost 30,000 newly diagnosed HIV infections were reported by the 31 European Union and European Economic Area (EU/EEA) countries in 2015, according to data published today by ECDC and the WHO Regional Office for Europe.
Smoking may shorten the lifespan of people living with HIV more than HIV itself
A new study led by researchers at Massachusetts General Hospital finds that cigarette smoking substantially reduces the lifespan of people living with HIV in the US, potentially even more than HIV itself.
For smokers with HIV, smoking may now be more harmful than HIV itself
HIV-positive individuals who smoke cigarettes may be more likely to die from smoking-related disease than the infection itself, according to a new study published in the Journal of Infectious Diseases.
Patients diagnosed late with HIV infection are more likely to transmit HIV to others
An estimated 1.2 million people live with HIV in the United States, with nearly 13 percent being unaware of their infection.
More Hiv News and Hiv Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#534 Bacteria are Coming for Your OJ
What makes breakfast, breakfast? Well, according to every movie and TV show we've ever seen, a big glass of orange juice is basically required. But our morning grapefruit might be in danger. Why? Citrus greening, a bacteria carried by a bug, has infected 90% of the citrus groves in Florida. It's coming for your OJ. We'll talk with University of Maryland plant virologist Anne Simon about ways to stop the citrus killer, and with science writer and journalist Maryn McKenna about why throwing antibiotics at the problem is probably not the solution. Related links: A Review of the Citrus Greening...